nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—urinary bladder cancer	0.351	1	CbGaD
Etoricoxib—PTGS2—Cisplatin—urinary bladder cancer	0.0508	0.184	CbGbCtD
Etoricoxib—PTGS2—Etoposide—urinary bladder cancer	0.0499	0.181	CbGbCtD
Etoricoxib—CYP3A4—Thiotepa—urinary bladder cancer	0.0364	0.132	CbGbCtD
Etoricoxib—CYP2E1—Etoposide—urinary bladder cancer	0.0326	0.118	CbGbCtD
Etoricoxib—CYP1A2—Fluorouracil—urinary bladder cancer	0.0226	0.0818	CbGbCtD
Etoricoxib—CYP2C9—Fluorouracil—urinary bladder cancer	0.0203	0.0737	CbGbCtD
Etoricoxib—CYP1A2—Etoposide—urinary bladder cancer	0.0188	0.0683	CbGbCtD
Etoricoxib—CYP2C9—Cisplatin—urinary bladder cancer	0.0173	0.0626	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—urinary bladder cancer	0.0106	0.0384	CbGbCtD
Etoricoxib—CYP3A4—Etoposide—urinary bladder cancer	0.00987	0.0358	CbGbCtD
Etoricoxib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00673	0.0244	CbGbCtD
Etoricoxib—CYP2C19—urine—urinary bladder cancer	0.0045	0.0849	CbGeAlD
Etoricoxib—MAPK14—prostate gland—urinary bladder cancer	0.0038	0.0717	CbGeAlD
Etoricoxib—CYP1A2—urine—urinary bladder cancer	0.00368	0.0694	CbGeAlD
Etoricoxib—CYP2C9—urine—urinary bladder cancer	0.00349	0.0658	CbGeAlD
Etoricoxib—CYP2E1—urine—urinary bladder cancer	0.00331	0.0624	CbGeAlD
Etoricoxib—MAPK14—epithelium—urinary bladder cancer	0.00279	0.0527	CbGeAlD
Etoricoxib—MAPK14—smooth muscle tissue—urinary bladder cancer	0.00269	0.0508	CbGeAlD
Etoricoxib—CYP3A4—urine—urinary bladder cancer	0.00266	0.0502	CbGeAlD
Etoricoxib—CYP2D6—urine—urinary bladder cancer	0.00262	0.0494	CbGeAlD
Etoricoxib—MAPK14—renal system—urinary bladder cancer	0.00259	0.0489	CbGeAlD
Etoricoxib—MAPK14—female reproductive system—urinary bladder cancer	0.00208	0.0392	CbGeAlD
Etoricoxib—MAPK14—vagina—urinary bladder cancer	0.00188	0.0354	CbGeAlD
Etoricoxib—MAPK14—lymph node—urinary bladder cancer	0.00121	0.0229	CbGeAlD
Etoricoxib—CYP2E1—prostate gland—urinary bladder cancer	0.00119	0.0224	CbGeAlD
Etoricoxib—PTGS2—prostate gland—urinary bladder cancer	0.00109	0.0206	CbGeAlD
Etoricoxib—CYP2E1—seminal vesicle—urinary bladder cancer	0.001	0.0189	CbGeAlD
Etoricoxib—PTGS2—seminal vesicle—urinary bladder cancer	0.000925	0.0174	CbGeAlD
Etoricoxib—CYP1A2—renal system—urinary bladder cancer	0.0009	0.017	CbGeAlD
Etoricoxib—CYP2E1—renal system—urinary bladder cancer	0.000809	0.0153	CbGeAlD
Etoricoxib—PTGS2—epithelium—urinary bladder cancer	0.000803	0.0152	CbGeAlD
Etoricoxib—CYP2C19—vagina—urinary bladder cancer	0.000798	0.0151	CbGeAlD
Etoricoxib—CYP2E1—urethra—urinary bladder cancer	0.000795	0.015	CbGeAlD
Etoricoxib—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000774	0.0146	CbGeAlD
Etoricoxib—PTGS2—renal system—urinary bladder cancer	0.000745	0.0141	CbGeAlD
Etoricoxib—PTGS2—urethra—urinary bladder cancer	0.000732	0.0138	CbGeAlD
Etoricoxib—CYP2C9—female reproductive system—urinary bladder cancer	0.000684	0.0129	CbGeAlD
Etoricoxib—CYP3A4—renal system—urinary bladder cancer	0.000651	0.0123	CbGeAlD
Etoricoxib—CYP2E1—female reproductive system—urinary bladder cancer	0.000648	0.0122	CbGeAlD
Etoricoxib—CYP2D6—renal system—urinary bladder cancer	0.000641	0.0121	CbGeAlD
Etoricoxib—PTGS2—female reproductive system—urinary bladder cancer	0.000597	0.0113	CbGeAlD
Etoricoxib—PTGS2—vagina—urinary bladder cancer	0.00054	0.0102	CbGeAlD
Etoricoxib—CYP3A4—female reproductive system—urinary bladder cancer	0.000521	0.00984	CbGeAlD
Etoricoxib—CYP2D6—female reproductive system—urinary bladder cancer	0.000513	0.00968	CbGeAlD
Etoricoxib—PTGS2—lymph node—urinary bladder cancer	0.000349	0.00659	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—urinary bladder cancer	0.000337	1	CrCbGaD
Etoricoxib—Haematuria—Epirubicin—urinary bladder cancer	0.000123	0.000656	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—urinary bladder cancer	0.000122	0.000655	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000122	0.000651	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000122	0.000651	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000122	0.00065	CcSEcCtD
Etoricoxib—Weight increased—Doxorubicin—urinary bladder cancer	0.000121	0.000649	CcSEcCtD
Etoricoxib—Epistaxis—Epirubicin—urinary bladder cancer	0.000121	0.000649	CcSEcCtD
Etoricoxib—Pruritus—Gemcitabine—urinary bladder cancer	0.000121	0.000648	CcSEcCtD
Etoricoxib—Nausea—Thiotepa—urinary bladder cancer	0.000121	0.000647	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—urinary bladder cancer	0.000121	0.000647	CcSEcCtD
Etoricoxib—Sinusitis—Epirubicin—urinary bladder cancer	0.000121	0.000645	CcSEcCtD
Etoricoxib—Feeling abnormal—Etoposide—urinary bladder cancer	0.00012	0.000645	CcSEcCtD
Etoricoxib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00012	0.000644	CcSEcCtD
Etoricoxib—Pneumonia—Doxorubicin—urinary bladder cancer	0.00012	0.00064	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00012	0.00064	CcSEcCtD
Etoricoxib—Pruritus—Fluorouracil—urinary bladder cancer	0.000119	0.000637	CcSEcCtD
Etoricoxib—Infestation—Doxorubicin—urinary bladder cancer	0.000119	0.000636	CcSEcCtD
Etoricoxib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000119	0.000636	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—urinary bladder cancer	0.000119	0.000636	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000118	0.000631	CcSEcCtD
Etoricoxib—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000118	0.000629	CcSEcCtD
Etoricoxib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000117	0.000627	CcSEcCtD
Etoricoxib—Renal failure—Doxorubicin—urinary bladder cancer	0.000117	0.000625	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000117	0.000624	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000117	0.000624	CcSEcCtD
Etoricoxib—Urticaria—Etoposide—urinary bladder cancer	0.000116	0.000622	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—urinary bladder cancer	0.000116	0.00062	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—urinary bladder cancer	0.000116	0.00062	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—urinary bladder cancer	0.000116	0.00062	CcSEcCtD
Etoricoxib—Abdominal pain—Etoposide—urinary bladder cancer	0.000116	0.000618	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000116	0.000618	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000116	0.000618	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—urinary bladder cancer	0.000115	0.000617	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—urinary bladder cancer	0.000115	0.000617	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—urinary bladder cancer	0.000115	0.000616	CcSEcCtD
Etoricoxib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000115	0.000616	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—urinary bladder cancer	0.000115	0.000615	CcSEcCtD
Etoricoxib—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000115	0.000614	CcSEcCtD
Etoricoxib—Asthenia—Cisplatin—urinary bladder cancer	0.000115	0.000613	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—urinary bladder cancer	0.000114	0.000613	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000114	0.000612	CcSEcCtD
Etoricoxib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000114	0.00061	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000114	0.000608	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—urinary bladder cancer	0.000113	0.000607	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000113	0.000607	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000113	0.000605	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000112	0.000602	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—urinary bladder cancer	0.000112	0.0006	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—urinary bladder cancer	0.000112	0.000598	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—urinary bladder cancer	0.000112	0.000597	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—urinary bladder cancer	0.000111	0.000596	CcSEcCtD
Etoricoxib—Dizziness—Fluorouracil—urinary bladder cancer	0.000111	0.000596	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—urinary bladder cancer	0.000111	0.000595	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000111	0.000594	CcSEcCtD
Etoricoxib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000109	0.000584	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000109	0.000584	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—urinary bladder cancer	0.000109	0.000583	CcSEcCtD
Etoricoxib—Vomiting—Gemcitabine—urinary bladder cancer	0.000109	0.000583	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—urinary bladder cancer	0.000108	0.000578	CcSEcCtD
Etoricoxib—Rash—Gemcitabine—urinary bladder cancer	0.000108	0.000578	CcSEcCtD
Etoricoxib—Dermatitis—Gemcitabine—urinary bladder cancer	0.000108	0.000577	CcSEcCtD
Etoricoxib—Eye disorder—Epirubicin—urinary bladder cancer	0.000108	0.000577	CcSEcCtD
Etoricoxib—Hypersensitivity—Etoposide—urinary bladder cancer	0.000108	0.000576	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—urinary bladder cancer	0.000108	0.000576	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—urinary bladder cancer	0.000107	0.000574	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—urinary bladder cancer	0.000107	0.000574	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000107	0.000574	CcSEcCtD
Etoricoxib—Headache—Gemcitabine—urinary bladder cancer	0.000107	0.000574	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—urinary bladder cancer	0.000107	0.000573	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000107	0.000573	CcSEcCtD
Etoricoxib—Vomiting—Fluorouracil—urinary bladder cancer	0.000107	0.000573	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000107	0.000571	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—urinary bladder cancer	0.000107	0.000571	CcSEcCtD
Etoricoxib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000106	0.000568	CcSEcCtD
Etoricoxib—Rash—Fluorouracil—urinary bladder cancer	0.000106	0.000568	CcSEcCtD
Etoricoxib—Dermatitis—Fluorouracil—urinary bladder cancer	0.000106	0.000567	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000106	0.000567	CcSEcCtD
Etoricoxib—Headache—Fluorouracil—urinary bladder cancer	0.000105	0.000564	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000105	0.000564	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000105	0.000563	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—urinary bladder cancer	0.000105	0.000562	CcSEcCtD
Etoricoxib—Asthenia—Etoposide—urinary bladder cancer	0.000105	0.000561	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000105	0.000561	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—urinary bladder cancer	0.000105	0.00056	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000105	0.00056	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—urinary bladder cancer	0.000104	0.000558	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000104	0.000556	CcSEcCtD
Etoricoxib—Pruritus—Etoposide—urinary bladder cancer	0.000103	0.000554	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—urinary bladder cancer	0.000103	0.000551	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—urinary bladder cancer	0.000103	0.00055	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—urinary bladder cancer	0.000102	0.000545	CcSEcCtD
Etoricoxib—Nausea—Gemcitabine—urinary bladder cancer	0.000102	0.000544	CcSEcCtD
Etoricoxib—Vomiting—Cisplatin—urinary bladder cancer	0.000101	0.000543	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—urinary bladder cancer	0.000101	0.000541	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—urinary bladder cancer	0.000101	0.000541	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000101	0.00054	CcSEcCtD
Etoricoxib—Rash—Cisplatin—urinary bladder cancer	0.000101	0.000538	CcSEcCtD
Etoricoxib—Dermatitis—Cisplatin—urinary bladder cancer	0.000101	0.000538	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—urinary bladder cancer	0.0001	0.000537	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—urinary bladder cancer	0.0001	0.000537	CcSEcCtD
Etoricoxib—Diarrhoea—Etoposide—urinary bladder cancer	0.0001	0.000535	CcSEcCtD
Etoricoxib—Nausea—Fluorouracil—urinary bladder cancer	0.0001	0.000535	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—urinary bladder cancer	9.97e-05	0.000534	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—urinary bladder cancer	9.95e-05	0.000533	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—urinary bladder cancer	9.92e-05	0.000531	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.91e-05	0.00053	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—urinary bladder cancer	9.91e-05	0.00053	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—urinary bladder cancer	9.9e-05	0.000529	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—urinary bladder cancer	9.83e-05	0.000526	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—urinary bladder cancer	9.68e-05	0.000518	CcSEcCtD
Etoricoxib—Dizziness—Etoposide—urinary bladder cancer	9.67e-05	0.000517	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—urinary bladder cancer	9.65e-05	0.000517	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—urinary bladder cancer	9.64e-05	0.000516	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.62e-05	0.000515	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—urinary bladder cancer	9.54e-05	0.00051	CcSEcCtD
Etoricoxib—Nausea—Cisplatin—urinary bladder cancer	9.48e-05	0.000507	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—urinary bladder cancer	9.46e-05	0.000506	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—urinary bladder cancer	9.43e-05	0.000505	CcSEcCtD
Etoricoxib—Cough—Methotrexate—urinary bladder cancer	9.36e-05	0.000501	CcSEcCtD
Etoricoxib—Mental disorder—Doxorubicin—urinary bladder cancer	9.35e-05	0.0005	CcSEcCtD
Etoricoxib—Vomiting—Etoposide—urinary bladder cancer	9.3e-05	0.000497	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—urinary bladder cancer	9.29e-05	0.000497	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—urinary bladder cancer	9.29e-05	0.000497	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—urinary bladder cancer	9.28e-05	0.000497	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—urinary bladder cancer	9.23e-05	0.000494	CcSEcCtD
Etoricoxib—Rash—Etoposide—urinary bladder cancer	9.22e-05	0.000493	CcSEcCtD
Etoricoxib—Dermatitis—Etoposide—urinary bladder cancer	9.21e-05	0.000493	CcSEcCtD
Etoricoxib—Headache—Etoposide—urinary bladder cancer	9.16e-05	0.00049	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—urinary bladder cancer	9.16e-05	0.00049	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—urinary bladder cancer	9.14e-05	0.000489	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—urinary bladder cancer	9.14e-05	0.000489	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—urinary bladder cancer	9.1e-05	0.000487	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.07e-05	0.000485	CcSEcCtD
Etoricoxib—Muscle spasms—Doxorubicin—urinary bladder cancer	8.93e-05	0.000478	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—urinary bladder cancer	8.87e-05	0.000475	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—urinary bladder cancer	8.83e-05	0.000473	CcSEcCtD
Etoricoxib—Cough—Epirubicin—urinary bladder cancer	8.76e-05	0.000469	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.76e-05	0.000469	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—urinary bladder cancer	8.76e-05	0.000469	CcSEcCtD
Etoricoxib—Infection—Methotrexate—urinary bladder cancer	8.7e-05	0.000466	CcSEcCtD
Etoricoxib—Nausea—Etoposide—urinary bladder cancer	8.68e-05	0.000465	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—urinary bladder cancer	8.67e-05	0.000464	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—urinary bladder cancer	8.59e-05	0.00046	CcSEcCtD
Etoricoxib—Anaemia—Doxorubicin—urinary bladder cancer	8.59e-05	0.00046	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.57e-05	0.000459	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—urinary bladder cancer	8.55e-05	0.000457	CcSEcCtD
Etoricoxib—Arthralgia—Epirubicin—urinary bladder cancer	8.55e-05	0.000457	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—urinary bladder cancer	8.54e-05	0.000457	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—urinary bladder cancer	8.52e-05	0.000456	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—urinary bladder cancer	8.51e-05	0.000455	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.49e-05	0.000454	CcSEcCtD
Etoricoxib—Dry mouth—Epirubicin—urinary bladder cancer	8.36e-05	0.000447	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—urinary bladder cancer	8.35e-05	0.000447	CcSEcCtD
Etoricoxib—Confusional state—Epirubicin—urinary bladder cancer	8.26e-05	0.000442	CcSEcCtD
Etoricoxib—Palpitations—Doxorubicin—urinary bladder cancer	8.21e-05	0.000439	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—urinary bladder cancer	8.2e-05	0.000439	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.2e-05	0.000439	CcSEcCtD
Etoricoxib—Infection—Epirubicin—urinary bladder cancer	8.14e-05	0.000436	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—urinary bladder cancer	8.11e-05	0.000434	CcSEcCtD
Etoricoxib—Shock—Epirubicin—urinary bladder cancer	8.06e-05	0.000431	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—urinary bladder cancer	8.04e-05	0.00043	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.02e-05	0.000429	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—urinary bladder cancer	8.02e-05	0.000429	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.98e-05	0.000427	CcSEcCtD
Etoricoxib—Skin disorder—Epirubicin—urinary bladder cancer	7.96e-05	0.000426	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—urinary bladder cancer	7.92e-05	0.000424	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—urinary bladder cancer	7.91e-05	0.000423	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—urinary bladder cancer	7.91e-05	0.000423	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—urinary bladder cancer	7.88e-05	0.000422	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.86e-05	0.00042	CcSEcCtD
Etoricoxib—Anorexia—Epirubicin—urinary bladder cancer	7.81e-05	0.000418	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—urinary bladder cancer	7.81e-05	0.000418	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—urinary bladder cancer	7.79e-05	0.000417	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—urinary bladder cancer	7.74e-05	0.000414	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—urinary bladder cancer	7.71e-05	0.000412	CcSEcCtD
Etoricoxib—Confusional state—Doxorubicin—urinary bladder cancer	7.65e-05	0.000409	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—urinary bladder cancer	7.61e-05	0.000407	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—urinary bladder cancer	7.58e-05	0.000406	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.58e-05	0.000406	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.56e-05	0.000405	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—urinary bladder cancer	7.55e-05	0.000404	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—urinary bladder cancer	7.53e-05	0.000403	CcSEcCtD
Etoricoxib—Pain—Methotrexate—urinary bladder cancer	7.49e-05	0.000401	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.47e-05	0.0004	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—urinary bladder cancer	7.46e-05	0.000399	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.44e-05	0.000398	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.42e-05	0.000397	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—urinary bladder cancer	7.41e-05	0.000397	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—urinary bladder cancer	7.37e-05	0.000394	CcSEcCtD
Etoricoxib—Dyspnoea—Epirubicin—urinary bladder cancer	7.31e-05	0.000391	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—urinary bladder cancer	7.29e-05	0.00039	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—urinary bladder cancer	7.23e-05	0.000387	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—urinary bladder cancer	7.22e-05	0.000386	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—urinary bladder cancer	7.21e-05	0.000386	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.16e-05	0.000383	CcSEcCtD
Etoricoxib—Decreased appetite—Epirubicin—urinary bladder cancer	7.12e-05	0.000381	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.08e-05	0.000379	CcSEcCtD
Etoricoxib—Fatigue—Epirubicin—urinary bladder cancer	7.07e-05	0.000378	CcSEcCtD
Etoricoxib—Pain—Epirubicin—urinary bladder cancer	7.01e-05	0.000375	CcSEcCtD
Etoricoxib—Constipation—Epirubicin—urinary bladder cancer	7.01e-05	0.000375	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—urinary bladder cancer	6.96e-05	0.000372	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—urinary bladder cancer	6.92e-05	0.00037	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.91e-05	0.00037	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—urinary bladder cancer	6.86e-05	0.000367	CcSEcCtD
Etoricoxib—Dyspnoea—Doxorubicin—urinary bladder cancer	6.76e-05	0.000362	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—urinary bladder cancer	6.75e-05	0.000361	CcSEcCtD
Etoricoxib—Somnolence—Doxorubicin—urinary bladder cancer	6.74e-05	0.000361	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.7e-05	0.000359	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—urinary bladder cancer	6.68e-05	0.000357	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—urinary bladder cancer	6.59e-05	0.000353	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.55e-05	0.00035	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—urinary bladder cancer	6.54e-05	0.00035	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—urinary bladder cancer	6.51e-05	0.000348	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—urinary bladder cancer	6.48e-05	0.000347	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—urinary bladder cancer	6.48e-05	0.000347	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—urinary bladder cancer	6.48e-05	0.000347	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—urinary bladder cancer	6.45e-05	0.000345	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—urinary bladder cancer	6.28e-05	0.000336	CcSEcCtD
Etoricoxib—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.25e-05	0.000334	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.2e-05	0.000332	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—urinary bladder cancer	6.2e-05	0.000332	CcSEcCtD
Etoricoxib—Hypersensitivity—Epirubicin—urinary bladder cancer	6.04e-05	0.000323	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—urinary bladder cancer	6.02e-05	0.000322	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—urinary bladder cancer	5.99e-05	0.000321	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—urinary bladder cancer	5.99e-05	0.000321	CcSEcCtD
Etoricoxib—Asthenia—Epirubicin—urinary bladder cancer	5.88e-05	0.000315	CcSEcCtD
Etoricoxib—Pruritus—Epirubicin—urinary bladder cancer	5.8e-05	0.00031	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—urinary bladder cancer	5.79e-05	0.00031	CcSEcCtD
Etoricoxib—Diarrhoea—Epirubicin—urinary bladder cancer	5.61e-05	0.0003	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.59e-05	0.000299	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—urinary bladder cancer	5.57e-05	0.000298	CcSEcCtD
Etoricoxib—Rash—Methotrexate—urinary bladder cancer	5.52e-05	0.000295	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—urinary bladder cancer	5.52e-05	0.000295	CcSEcCtD
Etoricoxib—Headache—Methotrexate—urinary bladder cancer	5.49e-05	0.000294	CcSEcCtD
Etoricoxib—Asthenia—Doxorubicin—urinary bladder cancer	5.44e-05	0.000291	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—urinary bladder cancer	5.42e-05	0.00029	CcSEcCtD
Etoricoxib—Pruritus—Doxorubicin—urinary bladder cancer	5.37e-05	0.000287	CcSEcCtD
Etoricoxib—Vomiting—Epirubicin—urinary bladder cancer	5.21e-05	0.000279	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—urinary bladder cancer	5.2e-05	0.000278	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—urinary bladder cancer	5.19e-05	0.000278	CcSEcCtD
Etoricoxib—Rash—Epirubicin—urinary bladder cancer	5.17e-05	0.000277	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—urinary bladder cancer	5.16e-05	0.000276	CcSEcCtD
Etoricoxib—Headache—Epirubicin—urinary bladder cancer	5.13e-05	0.000275	CcSEcCtD
Etoricoxib—Dizziness—Doxorubicin—urinary bladder cancer	5.01e-05	0.000268	CcSEcCtD
Etoricoxib—Nausea—Epirubicin—urinary bladder cancer	4.87e-05	0.00026	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—urinary bladder cancer	4.82e-05	0.000258	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—urinary bladder cancer	4.78e-05	0.000256	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—urinary bladder cancer	4.78e-05	0.000256	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—urinary bladder cancer	4.75e-05	0.000254	CcSEcCtD
Etoricoxib—Nausea—Doxorubicin—urinary bladder cancer	4.5e-05	0.000241	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—HRAS—urinary bladder cancer	2.68e-05	0.000202	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP9—urinary bladder cancer	2.67e-05	0.000201	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ENO2—urinary bladder cancer	2.65e-05	0.0002	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	2.64e-05	0.000199	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.63e-05	0.000198	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NAT2—urinary bladder cancer	2.62e-05	0.000197	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.61e-05	0.000197	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—ERCC2—urinary bladder cancer	2.6e-05	0.000196	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TSC1—urinary bladder cancer	2.59e-05	0.000195	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.57e-05	0.000194	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.55e-05	0.000192	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EP300—urinary bladder cancer	2.53e-05	0.000191	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RBX1—urinary bladder cancer	2.52e-05	0.00019	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—EP300—urinary bladder cancer	2.48e-05	0.000187	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.48e-05	0.000187	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JAG1—urinary bladder cancer	2.47e-05	0.000186	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—SRC—urinary bladder cancer	2.46e-05	0.000186	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—SRC—urinary bladder cancer	2.42e-05	0.000182	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.4e-05	0.000181	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.36e-05	0.000178	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CDKN1A—urinary bladder cancer	2.35e-05	0.000177	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PTEN—urinary bladder cancer	2.35e-05	0.000177	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.34e-05	0.000176	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—RRM2—urinary bladder cancer	2.26e-05	0.00017	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—JAG1—urinary bladder cancer	2.25e-05	0.00017	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—FGFR3—urinary bladder cancer	2.25e-05	0.000169	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.24e-05	0.000169	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EP300—urinary bladder cancer	2.24e-05	0.000169	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.23e-05	0.000168	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.23e-05	0.000168	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.22e-05	0.000167	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.22e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.22e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.22e-05	0.000167	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.21e-05	0.000166	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.18e-05	0.000164	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—SRC—urinary bladder cancer	2.18e-05	0.000164	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—ESR1—urinary bladder cancer	2.17e-05	0.000164	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—urinary bladder cancer	2.16e-05	0.000163	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.16e-05	0.000162	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.14e-05	0.000162	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.12e-05	0.00016	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	2.09e-05	0.000158	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ENO2—urinary bladder cancer	2.09e-05	0.000158	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TNF—urinary bladder cancer	2.06e-05	0.000155	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.05e-05	0.000155	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.04e-05	0.000154	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KRAS—urinary bladder cancer	2.04e-05	0.000154	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.04e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	2.03e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.03e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.02e-05	0.000152	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KRAS—urinary bladder cancer	2e-05	0.000151	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—S100B—urinary bladder cancer	2e-05	0.000151	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—PPARG—urinary bladder cancer	1.98e-05	0.000149	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.95e-05	0.000147	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CREBBP—urinary bladder cancer	1.91e-05	0.000144	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—urinary bladder cancer	1.91e-05	0.000144	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—CREBBP—urinary bladder cancer	1.9e-05	0.000143	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDH1—urinary bladder cancer	1.9e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.00014	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.84e-05	0.000139	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.82e-05	0.000138	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—urinary bladder cancer	1.8e-05	0.000136	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NCOR1—urinary bladder cancer	1.8e-05	0.000135	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.79e-05	0.000135	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—urinary bladder cancer	1.78e-05	0.000134	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.74e-05	0.000131	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.74e-05	0.000131	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.74e-05	0.000131	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—urinary bladder cancer	1.73e-05	0.000131	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.72e-05	0.00013	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—urinary bladder cancer	1.7e-05	0.000128	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.000127	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.68e-05	0.000127	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.67e-05	0.000126	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NCOR1—urinary bladder cancer	1.64e-05	0.000124	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.61e-05	0.000122	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.61e-05	0.000122	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.6e-05	0.000121	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.6e-05	0.000121	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERBB2—urinary bladder cancer	1.6e-05	0.000121	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.59e-05	0.00012	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TERT—urinary bladder cancer	1.58e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.57e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.57e-05	0.000118	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.54e-05	0.000116	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERCC2—urinary bladder cancer	1.54e-05	0.000116	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—urinary bladder cancer	1.53e-05	0.000115	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.52e-05	0.000114	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000113	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.48e-05	0.000112	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.48e-05	0.000112	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.47e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.47e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.46e-05	0.00011	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGFR3—urinary bladder cancer	1.45e-05	0.00011	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—urinary bladder cancer	1.45e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTHFR—urinary bladder cancer	1.45e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.45e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—urinary bladder cancer	1.44e-05	0.000109	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000108	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.43e-05	0.000108	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ESR1—urinary bladder cancer	1.41e-05	0.000106	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000106	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.41e-05	0.000106	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.39e-05	0.000105	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000103	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1A—urinary bladder cancer	1.37e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTEN—urinary bladder cancer	1.37e-05	0.000103	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.36e-05	0.000102	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.34e-05	0.000101	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGFR3—urinary bladder cancer	1.33e-05	9.99e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.31e-05	9.91e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.31e-05	9.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EP300—urinary bladder cancer	1.3e-05	9.82e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.3e-05	9.8e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	9.74e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	9.74e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	9.73e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—SRC—urinary bladder cancer	1.27e-05	9.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.26e-05	9.51e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.26e-05	9.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.26e-05	9.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.25e-05	9.42e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.24e-05	9.33e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CREBBP—urinary bladder cancer	1.24e-05	9.32e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IGF1—urinary bladder cancer	1.22e-05	9.21e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.22e-05	9.19e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	9.16e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.21e-05	9.15e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	9.14e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.2e-05	9.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.2e-05	9.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.19e-05	8.94e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.15e-05	8.67e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	8.61e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—urinary bladder cancer	1.13e-05	8.51e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREBBP—urinary bladder cancer	1.13e-05	8.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RHOA—urinary bladder cancer	1.12e-05	8.43e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—urinary bladder cancer	1.11e-05	8.37e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.1e-05	8.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	8.18e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.05e-05	7.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—urinary bladder cancer	1.05e-05	7.91e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.05e-05	7.9e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	7.81e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RHOA—urinary bladder cancer	1.02e-05	7.69e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.01e-05	7.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.01e-05	7.6e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1e-05	7.56e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.98e-06	7.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	9.97e-06	7.51e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	9.97e-06	7.51e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.89e-06	7.46e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—urinary bladder cancer	9.84e-06	7.41e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.83e-06	7.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—urinary bladder cancer	9.82e-06	7.4e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.7e-06	7.31e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.7e-06	7.31e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.57e-06	7.21e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	9.55e-06	7.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CREBBP—urinary bladder cancer	9.45e-06	7.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—urinary bladder cancer	9.45e-06	7.12e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.41e-06	7.09e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—urinary bladder cancer	9.39e-06	7.08e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	9.37e-06	7.06e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.28e-06	6.99e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—urinary bladder cancer	9.26e-06	6.98e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.2e-06	6.93e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9.17e-06	6.91e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9.17e-06	6.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—urinary bladder cancer	9.15e-06	6.9e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.09e-06	6.85e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.09e-06	6.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—urinary bladder cancer	8.92e-06	6.72e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	8.9e-06	6.7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—urinary bladder cancer	8.89e-06	6.7e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—urinary bladder cancer	8.85e-06	6.67e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—urinary bladder cancer	8.83e-06	6.66e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.81e-06	6.64e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.78e-06	6.62e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.71e-06	6.56e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.62e-06	6.5e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.58e-06	6.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.55e-06	6.44e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	8.45e-06	6.37e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EP300—urinary bladder cancer	8.42e-06	6.35e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SRC—urinary bladder cancer	8.19e-06	6.17e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.18e-06	6.16e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	8.1e-06	6.11e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—urinary bladder cancer	8.08e-06	6.09e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—urinary bladder cancer	8.06e-06	6.07e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.03e-06	6.06e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.86e-06	5.92e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.82e-06	5.9e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.77e-06	5.85e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.77e-06	5.85e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EP300—urinary bladder cancer	7.69e-06	5.79e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SRC—urinary bladder cancer	7.47e-06	5.63e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.44e-06	5.61e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—urinary bladder cancer	7.34e-06	5.53e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.3e-06	5.5e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	7.28e-06	5.49e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—urinary bladder cancer	7.18e-06	5.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	7.14e-06	5.38e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.87e-06	5.17e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.86e-06	5.17e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—urinary bladder cancer	6.78e-06	5.11e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—urinary bladder cancer	6.75e-06	5.09e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—urinary bladder cancer	6.7e-06	5.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.57e-06	4.95e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—urinary bladder cancer	6.55e-06	4.94e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.52e-06	4.92e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.51e-06	4.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—EP300—urinary bladder cancer	6.44e-06	4.85e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—urinary bladder cancer	6.35e-06	4.79e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.31e-06	4.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.26e-06	4.72e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—urinary bladder cancer	6.19e-06	4.66e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.07e-06	4.57e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—EP300—urinary bladder cancer	6.06e-06	4.57e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—urinary bladder cancer	6.03e-06	4.54e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6e-06	4.52e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6e-06	4.52e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—urinary bladder cancer	5.77e-06	4.35e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.74e-06	4.33e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.64e-06	4.25e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.62e-06	4.24e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.57e-06	4.2e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.35e-06	4.03e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.3e-06	3.99e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—urinary bladder cancer	5.26e-06	3.96e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.17e-06	3.9e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.12e-06	3.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.9e-06	3.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.67e-06	3.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.51e-06	3.4e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.47e-06	3.37e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.38e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.3e-06	3.24e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.3e-06	3.24e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.26e-06	3.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.13e-06	3.11e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.82e-06	2.88e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.64e-06	2.75e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.38e-06	2.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.95e-06	2.22e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.81e-06	2.12e-05	CbGpPWpGaD
